(Q42627572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

29 February 2020

main subject

phase II clinical trial

0 references

1 reference

1 reference

chronic lymphocytic leukemia

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Emanuele Angelucci

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sonia Fabris

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Agostino Cortelezzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Gianluigi Reda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesco Zaja

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Annalisa Chiarenza

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Giuseppe Gritti

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesca Romana Mauro

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Marco Vignetti

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Antonino Neri

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Diana Giannarelli

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

M Sciumè

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A M Liberati

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D Vincenti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Cuneo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Laurenti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Orsucci

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Storti

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

N Cascavilla

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Gobbi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Morabito

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Piciocchi

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D Rossi

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Guarini

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Foà

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

13 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

642-648

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.334

29 February 2020

exact match

0 references

cites work

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.334

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

21 January 2018

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

12 December 2020

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.334

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 February 2020

1041581221

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24220274%20AND%20SRC:MED&resulttype=core&format=json